BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market. Recent $1B preferred equity raise secures BBIO's cash runway for at least 12 months, supporting ongoing NDA submissions and commercialization efforts.